Angioedema Associated with Candesartan

Incidence and Risk Profile

Angioedema with ARBs like candesartan is significantly less common than with ACE inhibitors, but the risk is not zero, according to the American College of Cardiology and other guideline societies 1, 2, 3

Patients with prior ACE inhibitor-induced angioedema can develop angioedema with candesartan, as reported in Circulation and the Journal of the American College of Cardiology 1, 2, 3
If an ARB must be used after ACE inhibitor-induced angioedema, a mandatory 6-week washout period is required before initiation, with careful monitoring, as recommended by the American College of Cardiology 4
The American College of Cardiology and American Heart Association guidelines state that "extreme caution is advised" when substituting an ARB in patients with ACE inhibitor-induced angioedema 4

If a patient has experienced angioedema with ANY ARB previously, candesartan is absolutely contraindicated, according to the American College of Cardiology and other guideline societies 4
Neprilysin inhibitors (ARNIs like sacubitril-valsartan) are absolutely contraindicated in any patient with a history of angioedema, as recommended by the American College of Cardiology and other guideline societies 4

Evidence regarding sex differences is contradictory: some studies show higher incidence in women, while a 2017 VigiBase analysis reported significantly higher angioedema rates with ARBs in men compared to women, according to Pharmacology and Therapeutics 5